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HBV infection is an important worldwide cause of morbidity and 
mortality from cirrhosis and hepatocellular carcinoma (HCC). An 
estimated 257 million people are chronically infected worldwide. 
The disease is most prevalent in the WHO African and Western 
Pacific regions. The prevalence in the African region is 6.1%. 
Infection in the neonatal period and in childhood predisposes to 
chronic infection.[1-7] The WHO estimated that chronic hepatitis 
B resulted in 880 000 deaths from cirrhosis and hepatocellular 
carcinoma in 2015. Hepatitis B birth dose and universal HBV 
vaccination, together with third-trimester tenofovir in highly 
viraemic pregnant women, are highly effective in reducing incident 
chronic hepatitis B infection in endemic regions. However, the rates 
of end-stage liver disease in chronically infected persons will remain 
substantial as a large reservoir of chronic infection remains. This 
disease burden needs to be progressively eliminated worldwide. The 
present lack of curative therapy has spurred research into potential 
targets for novel drug development. Improved understanding of 
the pathobiology of the virus and the temporal but complex host 
immunological response is key to understanding the rationale, 
mechanism of action and appropriate combinations of newer, 
potentially curative treatments. 
Virology
Hepatitis B virus (HBV) is an enveloped 42 nm diameter DNA 
virus, of the Hepadnaviridae family, containing a partially double-
stranded relaxed circular DNA genome of 3 200 base pairs in 
length. The DNA is replicated via reverse transcription of a RNA 
pregenome within the capsid during packaging of the RNA and the 
viral reverse transcriptase. The virion binds to a cellular receptor, 
sodium taurocholate co-transporting polypeptide (NTCP), and 
is subsequently internalised into the cell. After entry into the 
cell, the first event in HBV DNA replication is conversion of the 
relaxed circular DNA genome into a covalently closed circular 
DNA (cccDNA) minichromosome in the nucleus of hepatocytes 
(Fig. 1).
cccDNA is the transcriptional template for transcription of the 
viral RNAs. cccDNA persists as a minichromosome in the nucleus of 
the infected cells. Importantly, cccDNA is synthesised from relaxed 
circular DNA (rcDNA), either from incoming infecting virions or 
from subsequent intracellular nucleocapsids via an intracellular 
cccDNA shuttle amplification pathway. The end product of reverse 
transcription, rcDNA is directed to the host cellular nucleus to form 
more cccDNA.[8,9] Packaging of the viral pre-genomic RNA (pgRNA) 
occurs as a complex with the HBV reverse transcriptase protein 
into an icosahedral 30 nm diameter capsid, composed of copies 
of the viral core. The HBV capsid is assembled into core particles, 
containing pgRNA and the viral polymerase (reverse transcriptase). 
Within the nucleocapsid, the pgRNA is reverse transcribed by the 
viral reverse transcriptase-polymerase to form incomplete rcDNA, 
and HBV capsids are subsequently coated with hepatitis B surface 
antigen (HBsAg) to form mature virus particles.[10]
Complete and incomplete viral particles are thus secreted into 
the circulation. Empty non-DNA-containing virions are exuded 
from the cell and can be detected in serum; importantly, recent 
findings have shown that RNA-containing particles are released. It 
is noteworthy that inhibition of cccDNA synthesis is not affected 
by current nucleoside analogue therapy, as only DNA synthesis 
is targeted. The product of the hepatitis Bx gene (HBx) has been 
shown to be necessary for the transcription from cccDNA through 
epigenetic regulation.[11,12] 
HBV DNA fragments are integrated into the genome of 
hepatocytes but integration is not a requirement for replication of 
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HBV. Hepatitis B e-antigen (HBeAg) is a 
soluble, dimeric protein that is secreted from 
hepatocytes. HBeAg is processed from the 
precore protein. The bulk of amino acids are 
shared with HBcAg, but HBeAg posseses an 
N-terminal extension of 10 amino acids and 
a C-terminal truncation of 34 amino acid 
residues. Serum HBeAg is associated with 
high levels of viral infection and can be used 
to monitor temporal changes and treatment 
response. HBsAg is also produced following 
transcription of integrated viral DNA.[13] The 
large envelope glycoprotein on the surface 
of HBV and hepatitis D virus (HDV) has 
been demonstrated to play a pivotal role 
in virus entry. The antigenic loop on the S 
protein mediates attachment to cell surface 
heparan sulfate proteoglycans (HSPGs).[14,15] 
There is variation in sequence (up to 12% 
of nucleotides) between isolates of HBV 
and up to nine genotypes (A to I) have been 
described on the basic nucleotide sequence 
divergence.
Natural history
The natural history of HBV infection 
is still being delineated. Most persons 
infected at birth or childhood develop 
persistent HBV infection.[1-3] Different, 
age-dependent phases of the disease have 
long been recognised (Table 1). In the 
high replicative, low inflammatory phase, 
HBsAg and HBeAg are detectable in serum, 
serum HBV DNA concentrations are high, 
but serum aminotransferases may be only 
minimally increased or normal. However, 
recent immunological reports have argued 
that antigen-specific immune responses 
exist in a proportion of these so-called 
immune-tolerant patients and that this 
phase of the disease is associated with 
clonal expansion of hepatocytes and viral 
integration. Adolescents may harbour 
hepatitis B functionally active specific T 
cells.[16] Serum alanine aminotransferase 
(ALT) is not a measure of immunological 
response. However, robust, functional 
and broadly specific T lymphocyte 
specificities are lacking, suggesting 
a degree of functional impairment and 
clonal tolerance.[17] In HBeAg-positive 
patients, progression to cirrhosis occurs 
at a rate of 2 - 5.5% per annum with a 
cumulative 5-year incidence of progression 
of 8 - 20%. The high replicative phase is 
followed by active chronic hepatitis with 
progressive necro-inflammatory disease, or 
by HBeAg seroconversion and remission 
in a proportion of patients (the inactive 
carrier state). Early seroconversion to 
anti-HBe may lead to remission of the 
disease and may confer a good prognosis, 
according to the degree of the liver damage. 
In HBeAg-positive persons a spontaneous 
remission is possible in about 10 - 15% 
of the cases per year. Inactive carriers 
characteristically manifest persistently 
normal aminotransferases and HBV 
DNA concentrations of <2 000 IU/mL. A 
proportion of HBsAg-positive persons lose 
HBsAg at a rate of 0. 5 - 2% per year. 
HBeAg-negative anti-HBe-positive 
disease is a common pattern of disease. 
HBeAg is undetectable in these persons 
owing to the selection of HBV virions 
not expressing HBeAg (pre-core mutant 
HBV). Several mutations in the pre-core 
region that preclude HBeAg synthesis 
have been identified in HBeAg-negative 
carriers, in whom histochemical detection 
of HBcAg in hepatocytes and histological 
evidence of active chronic hepatitis is 
present. Individuals with anti-HBe-positive 
chronic hepatitis B tend to be older, and 
have more progressive necro-inflammatory 
change. HBeAg-negative chronic hepatitis 
has a variable course, with fluctuating 
serum aminotransferases and HBV DNA 
concentrations. Progression to cirrhosis 
generally occurs more rapidy in anti-
HBe-positive disease at a yearly rate of 
8 - 20%. Levels of HBsAg and HBV DNA 
are generally lower than in HBeAg-positive 
patients. 
The reported 5-year cumulative incidence 
of hepatic decompensation in patients with 
cirrhosis is 16%. The cumulative probability 
of survival in 366 cases of HBsAg-positive 
compensated cirrhosis was 84% and 68% at 
5 and 10 years, respectively.[18-21] Risk factors 
associated with a high rate of progression 
have been identified and include age, male 
gender, high aminotransferases, high HBV 
DNA concentrations, high HBsAg levels, 
genotype C and basal core promoter 
expression. Higher rates of HCC have been 
found in individuals with genotypes C and 
F v. B or D.  HCC occurs at a younger age in 
those with genotypes F, or with subtypes of 
genotype A found in southern Africa.
HBV and the immune 
system
The outcome of the HBV infection is 
determined by the host immune response. 
Whereas 95% of immunocompetent 
adults clear the infection, only 
5 - 10% of the children resolve the acute 
infection. Resolution of acute hepatitis B 
is associated with functionally efficient, 
broadly specific antiviral T-cell responses, 
which are preceded by the induction of 
intracellular innate responses at the early 
stages of infection.[22] Persons resolving 
HBV infection have vigorous HBV-specific 
CD4+ and CD8+ T-cell repertoires and 
function when compared with chronic 
infection.[23,24] Long-lasting protective 
memory provides persistent control of 
infection, which is probably sustained by 
continuous stimulation of the immune 
system by residual amounts of virus. 
Chronic virus infection is characterised by 
a deeply dysfunctional immune response 
including a lack of protective memory 
T-cell maturation and an exhausted HBV-
specific T-cell response. T-cell exhaustion 
is thought to be the result of persistent 
exposure to soluble HBV antigens (HBeAg 
and HBsAg).[25] The liver environment 
may be tolerogenic. The degree of T-cell 
impairment is related to the level of HBV 
replication and antigen load.[26,27] Chronic 
Fig. 1. HBV replication cycle. (rc-DNA = relaxed circular DNA; HBV = hepatitis B virus; 
cccDNA = covalently closed circular DNA;  pgRNA = pre-genomic RNA.)
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HBV infection is characterised by a low frequency of HBV-specific 
CD8+ T-cell responses, an impaired production of interleukin 
(IL-2), an impaired proliferation of CD4+ T cells, an increase in the 
number of regulating T cells (Treg) in the liver and in the number of 
IL-10-secreting T cells.[28] Although T-cell responses can be detected 
in young adults, HBV-specific T cells are weak and functionally 
Table 1. Commonly defined phases of HBV disease
Stage
HBeAg and HBV DNA 
serological status Pattern Current treatment 
Potential curative 
treatment advantage
High replicative phase HBeAg-positive
High DNA concentrations
HBeAg-positive
High levels of HBV 
replication (high HBV DNA 
concentrations)
Minimal histological 
disease
Stage seen in many children
Interferon generally 
ineffective
Maintenance therapy 
nucleosides required
Benefit if HBsAg loss at 
early stage
Obviates progression
Most effective approach 
uncertain
Molecular inhibition of 
HBV replication?
Immune restoration?
HBeAg-active disease HBeAg-positive; may 
develop anti-HBe
Raised ALT
Histological activity
Lobular hepatitis, bridging 
fibrosis and fibrosis can be 
present
May progress to anti-HBe-
positive disease
HBeAg to anti-HBe 
seroconversion possible; 
normalisation of ALT
Suitable for treatment with 
nucleosides or interferon 
Direct inhibition
Immune activation 
feasible after viral 
replication suppressed; 
spontaneous HBeAg 
loss more likely with 
interferon or nucleoside 
analogue therapy 
HBeAg-negative disease HBeAg-negative, anti-HBe-
positive
HBeAg-negative disease
HBeAg-negative anti-HBe-
positive
Ongoing HBV replication
HBV DNA >20 000 IU/mL
Exacerbations of ALT
Older persons
Progressive disease 
Nucleoside analogue 
treatment
Less commonly, interferon
Direct inhibition may 
be advantageous
HBV replication easily 
suppressed 
Immune activation 
feasible but could be 
difficult to invoke as 
later stage of disease
Reactivation or acute-on-
chronic hepatitis
HBeAg-positive or HBeAg-
negative
HBV DNA elevated
Serum ALT elevated 
Seroreversion to HBeAg 
can occur if HBeAg-
negative
High risk of decom-
pensation if cirrhosis
Can be precipitated by 
immunosuppression
Nucleoside analogue 
treatment required
Curative treatment 
would prevent
Importance of 
prophylaxis
Points to importance 
of B-cell immunity 
in maintaining lower 
levels of replication: 
reactivation with B-cell 
depletion (anti-CD20) 
therapy
Urgent intervention 
required in clinical 
setting
Low replicative phase HBeAg-negative anti-HBe-
positive 
HBV DNA <2000 IU/mL
Risk of cirrhosis declines
HCC risk lower
Can develop anti-HBe-
positive disease 
Monitoring only Functional cure; 
Mechanism of 
maintained low level 
of replication requires 
emulation 
Low levels of HBsAg 
confer good prognosis 
HBV = hepatitis B virus; HBeAg = hepatitis B e-antigen; HBsAg = hepatitis B surface antigen; ALT = alanine aminotransferase.
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impaired. The hepatic inflammation is not 
proportional to the quantity of hepatitis 
B-specific CD8+ T cells.[23,24] Other factors 
such as chemokines and natural killer cell 
activation are important. The essential role 
of B cell immunity in clearance of hepatitis 
B and reactivation require further study.[29] 
Even at the early phase of HBV DNA 
integration, clonal expansion hepatocytes 
indicate that disease is underway. 
Current treatment of 
hepatis B
A large worldwide reservoir of chronic HBV 
infection remains. The objective of therapy 
is to prevent progression to cirrhosis, and 
end-stage liver disease, including HCC. 
Over the past three decades, conventional 
interferon alpha pegylated interferon 
alpha (PEG-IFNα), nucleotide analogues 
including lamivudine, adefovir, entecavir, 
telbivudine, tenofovir and emtricitabine 
have been shown to delay progression 
of cirrhosis, reduce but not eliminate 
the risk of HCC, improve survival, and 
reduce the need for liver transplantation.[30] 
The REVEAL studies[31,32] showed a 
reduction in HCC risk with lower HBV 
DNA concentrations. The efficacy of IFNα 
is restricted. Some pre-treatment and 
on-treatment factors predictive of response 
to PEG-IFNα have been identified, 
including genotype. Successful finite cures 
of hepatitis B are possible with interferon 
therapy, but are rare. HBsAg concentrations 
>20 000 IU/ml at treatment week 12 
have a high negative predictive value of 
unsuccessful treatment (irrespective of HBV 
genotype) in HBeAg-positive patients.[33] 
The side-effects of interferon treatment 
mitigated its current use. PEG IFNα 
added to tenofovir may result in greater 
suppression of HBsAg than treatment 
with the nucleoside alone.[34] Various 
combinations of, or sequential therapy 
with, PEG IFNα and nucleoside analogues 
reduce HBsAg synthesis, but PEG-IFNα has 
restricted efficacy (Fig. 2). 
HBV DNA replication can be successfully 
controlled, with nucleos(t)ide analogues 
that have a high barrier to resistance 
(entecavir and tenofovir), thus reducing 
the probability of adverse outcomes, 
but lifelong therapy is needed for the 
majority.[35] Unfortunately, a large burden 
of resistant HBV has been engendered in 
countries where sequential lamivudine and 
adefovir have been used. The sequential 
use of entecavir to treat lamivudine 
resistance increases the risk of entecavir 
resistance. A switch to tenofovir is effective 
in patients with confirmed lamivudine, 
telbivudine, adefovir or entecavir resistance. 
Nucleos(t)ide analogues with a high barrier 
to resistance are now recommended as first-
line therapy. A reduced incidence of HCC 
with long-term nucleoside-analogue therapy 
compared with controls has been reported in 
cirrhotic patients.[36-38]
The prospects of a cure 
of hepatitis B
A functional cure could be characterised 
as resulting in a sustained loss of HBsAg, 
which is associated with improved clinical 
outcomes. A complete sterilising cure with 
undetectable HBsAg in serum and eradication 
of intrahepatic cccDNA, as well as integrated 
cccDNA, is not presently feasible. Also, loss 
of HBsAg later in life after the development 
of cirrhosis will not eliminate the risk of 
HCC. New molecular therapeutics and 
immunological strategies are emerging, but 
the stable and resistant reservoir of episomal 
cccDNA and a dysfunctional or ineffective 
immune response impedes cure at present. 
Combinations of, or sequential therapy with, 
PEG IFNα and nucleoside analogues reduce 
HBsAg synthesis, but the effects on cure are 
limited.[39,40] 
Nucleoside analogues compete at the 
HBV polymerase catalytic site during 
synthesis of nascent HBV DNA, preventing 
the formation of a covalent bond with the 
adjoining nucleotide, and thus causing 
chain termination of the elongating DNA. 
Nucleosides suppress cccDNA amplification 
but do not act on preformed cccDNA.[41] The 
stable maintenance and function of cccDNA 
pools in the nuclei of infected cells provides a 
continued source of viral RNA transcripts and 
generally precludes curing with nucleoside 
analogue therapy and nessitates lifelong 
therapy.
Finite therapy with nucleosides or interferon 
can result in HBsAg loss in some patients[42,43] 
and may be predicted by HBsAg levels in 
HBeAg negative patients.[44] Consolidation 
therapy after HBsAg loss is advisable.[45] 
Long-term (more than 4-year) entecavir or 
tenofovir therapy can be discontinued for 
non-cirrhotic HBeAg-negative patients if 
close follow-up is possible, as the cumulative 
rates of virological relapse are high at 67% 
and 31%, respectively, with serum HBV 
DNA cutoff values of >20 000 IU/mL and 
>2 000 IU/L, respectively. The probability 
of relapse seems to diminish 6 months after 
cessation of treatment.[46,47] There would be 
several potential benefits of finite therapy 
with nucleos(t)ide analogues, including 
improved adherence and cost savings for 
healthcare systems.
Potential new treatments 
Several recent reviews have summarised 
prospective treatments.[48-50] A full review of 
potential curative strategies is beyond the 
scope of this article, but prospective new 
compounds are reviewed in two recent 
Fig. 2. HBV cure: Mechanisms under investigation. (HBV = hepatitis B virus; rcDNA = relaxed circular 
DNA; cccDNA = covalently closed DNA; pgRNA = pre-genomic RNA; HBsAg = hepatitis B surface 
antigen.)
Fig. 3. HBV antiviral targets: A summary. (cccDNA = covalently closed circular DNA.)
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publications.[51,52] However, cure of hepatitis 
B is the next goal of therapy of hepatitis B 
(Fig. 3).
Tenofovir alafenamide fumarate (TAF) is an 
oral phosphonoamidate prodrug of tenofovir. 
Uptake of the parent nucleotide and its active 
diphosphate metabolite into lymphoid cells 
and hepatocytes is enhanced due to improved 
plasma stability and a different intracellular 
activation mechanism for TAF. 
Similar rates of viral suppression but 
higher rates of ALT normalisation with TAF 
have been reported. Switching to TAF results 
in improvements in bone density and renal 
function.[53,54] Similarly,  TAF has a high 
barrier to resistance but is not likely to 
improve rates of cure.[55-57] Other nucleosides 
in the pipeline include besifovir.[58]
Several new inhibitory molecules are 
being investigated. These include entry 
inhibitors, short interfering RNA (siRNAs), 
or capsid inhibitors (Fig. 4).[49]
Entry inhibitors 
The sodium taurocholate co-transporting 
polypeptide has recently been recognised 
as the HBV (and HDV) receptor.[59] A 
synthesised acylated pre-S peptide derivative 
of the large HBsAg protein blocks entry of 
HBV in experimental cells (Myrcludex B; 
MYR GmbH, Burgwedel) and is currently 
being studied in chronic HBV and HDV 
infection.[60] Encouraging phase 1 and 2 
studies with nucleosides and interferon 
are in progress. Parenterally administered 
neutralising antibodies are a potential 
alternative approach. 
Targeting cccDNA
Relaxed, unwound chromatin is associated 
with the activation of gene expression and, in 
contrast, compacted chromatin is associated 
with repression of gene expression. 
Epigenetic regulation of transcription could 
potentially disrupt transcription from 
cccDNA. cccDNA contains methylation-
prone CpG islands[61] and thus epigenetic 
silencing of cccDNA transcription may be 
possible.[62-65] Two classes of enzymes, 
histone deacetylases (HDACs) and histone 
acetyltransferases (HATs), regulate the 
acetylation status of histones; post-
translational modification of histones by 
acetylation, phosphorylation, methylation 
and ubiquitylation reactions could 
potentially be targeted (Fig. 5). 
cccDNA within infected hepatocytes 
could be degraded. HBx is required for 
cccDNA transcription and viral replication 
(via degradation of the Smc5/6 restriction 
factor) and is an attractive target (Fig. 
6).[66] Assays to detect cccDNA have, 
unfortunately, not been standardised. 
Lymphotoxin-β receptor signalling has been 
shown to activate upregulation of cytidine 
deaminases.[67] Lucifora et al.[67] have shown 
that IFNα induces specific degradation of 
the nuclear viral DNA; their experimental 
data suggest that IFNα activation and 
activation of the lymphotoxin-β receptor 
upregulates APOBEC3A and APOBEC3B, 
two cytidine deaminases, in HBV-infected 
cells, primary hepatocytes and human liver 
tissue specimens, to degrade cccDNA.[67] 
DNA cleavage enzymes, including CRISPR-
associated nucleases, are being tested in 
experimental models. Mutational inactivation 
of HBV DNA by clustered, short palindromic 
repeats (CRISPRs) and CRISPR-associated 
(Cas) proteins is a powerful tool to potentially 
induce cleavage of specific HBV DNA targets, 
after direction by a synthetic guide RNA base-
paired to the target HBV DNA sequence.[68,69] 
The CRISPR/Cas9 system has been shown 
to diminish production of HBV capsid and 
surface proteins in Huh-7 transfected cells. 
Recently Seeger et al.[70] established HepG2 
cells expressing the NTCP receptor that are 
susceptible to HBV infection. Guide RNAs 
inhibited HBcAg expression in HepG2 
cells, which showed that CRISPR/Cas9 
mechanisms for efficient inactivation of viral 
genes targeting cccDNA may be possible. 
Potential off-target effects will need to be 
addressed before they can be tested in clinical 
trials. 
Targeting viral transcripts
Antisense, siRNA targeting is being tested. 
siRNA can be engineered to target HBsAg 
Fig. 4. Potential HBV antiviral targets.  (HBV = hepatitis B virus;  rcDNA = relaxed circular DNA; 
HBsAg = hepatitis B surface antigen; cccDNA = covalently closed circular DNA; pgRNA = pre-genomic 
RNA.)
Fig. 5. Targeting cccDNA. (rcDNA = relaxed circular DNA;  cccDNA = covalently closed DNA; 
HBV = hepatitis B virus; IFNα = interferon-alpha; IL-6 = interleukin-6; LTβR-agonist = lymphotoxin-
beta receptor; TNF = tumour necrosis factor; IFNγ = interferon-gamma.)
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transcripts and subsequent degradation 
of the mRNA. Several antisense siRNA 
formulations are under clinical or preclinical 
evaluation. ARC 520 is a RNA interference 
(RNAi)-based, liver-targeted antiviral 
RNA comprising a combination of two 
cholesterol-conjugated siRNA molecules 
that directly target HBV RNA transcripts 
to trigger sequence-specific knock-down 
modulation of gene expression, and thus 
reduce HBV DNA and viral proteins.[71-76] 
Prolonged RNAi therapy with ARC-520 
in treatment-naive, HBeAg-positive and 
HBeAg-negative patients with chronic HBV 
results in significant reductions in HBsAg.[75] 
The reduction in HBeAg-positive patients 
is greater than in HBeAg-negative patients, 
which probably reflects reductions in HBsAg 
from cccDNA in the former v. integrated 
DNA in HBeAg negative patients. A phase 
2a study evaluating the multi-dose activity of 
ARB-1467 in HBeAg-positive and HBeAg-
negative virally suppressed patients with 
HBV has been reported. ARB-1467 is given 
by injection (2 mg/mL) IV over 2 hours 
for 3 months; pre-medications (including 
steroids) were given to mitigate infusion-
related adverse events. Significant reductions 
in HBsAg with single doses of ARB-1467 
0.2 mg/kg and 0.4 mg/kg were noted with 
stepwise, additive reductions with multiple 
doses. There were no significant differences 
in serum HBsAg between HBeAg-negative 
and HBeAg-positive patients.[77] Currently 
a potential limitation is the need for 
intravenous administration, the possibility 
of off-target binding and the potential 
toxicity of the excipient. Studies are required 
to determine whether knockdown of 
HBsAg will restore antigen-specific immune 
responsiveness.[78]
Nucleic acid polymers are oligonucleo-
tides with antiviral activity but which are 
not sequence dependent. Several phase II 
clinical trials, including in combination 
with interferon, are in progress and have 
demonstrated a profound decline in serum 
HBsAg concentrations. The compounds 
under investigation, REP 2139-Mg or REP 
2165-Mg used in combination with tenofovir 
and PEG-IFNa and given by intravenous 
infusion, block the entry and formation 
of subviral particles by interfering with 
apolipoprotein-HBsAg interactions.[52,79,80] 
The selective effect of REP 2139-Mg on 
serum HBsAg is consistent with the targeting 
of subviral particle release in cells. 
Capsid inhibitors
Because of the pivotal interaction between 
the HBV nucleocapsid and cccDNA, the 
HBV capsid is a crucial potential target. HBV 
replication is in part regulated by the kinetics 
of assembly of the nucleocapsid particle, 
which comprises the viral capsid proteins, 
HBV polymerase and pre-genomic RNA 
(reviewed by Berke et al.).[81] Thus inhibitors 
of either encapsidation, or compounds that 
result in capsid dissembly, impede the entry of 
rcDNA into the nucleus and could thus inhibit 
transformation of rcDNA to cccDNA. A 
number of compounds active against the HBV 
core are in development. Capsid assembly 
modulators (CAMs) hasten the kinetics of 
the HBV nucleocapsid complex assembly 
and thereby prevent the encapsidation of 
the polymerase-pgRNA composite and block 
the reverse transcription of the pgRNA. 
Moreover, HBV core protein regulates 
cccDNA transcription and replication steps, 
perhaps via reducing acetylation of cccDNA-
bound histones (Fig. 7). Thus, HBsAg levels 
may be reduced (Fig. 2).
Several compound classes have been 
reported to disrupt polymerase-pgRNA 
encapsidation at the nucleation step, resulting 
in either empty or intact capsids (a class I 
mechanism of action) or alternatively affect 
the formation of pleiomorphic noncapsid 
structures referred to as class II compounds. 
Recently, some capsid inhibitors have 
also been found to reduce intrahepatic 
cccDNA concentrations.[82] AB-423 (a capsid 
inhibitor) misdirects capsid assembly and 
thus inhibits pgRNA encapsidation. AB-423 
exhibits a dual mode of action in C3AhNTCP 
cells, namely inhibition of encapsidation of 
Fig. 7. Nucleocapsid assembly targeting. (HBV = hepatitis B virus;  pgRNA = pre-genomic RNA; 
HBcAg = hepatitis B c-antigen.)
Fig. 6. Nucleoside analogues have little effect on cccDNA but capsid assembly modulators may result 
in diminution of cccDNA. Continued transcription of HBsAg occurs from cccDNA and integrated 
viral genomes. (HBV = hepatitis B virus; rcDNA = relaxed circular DNA; cccDNA =  covalently closed 
circular DNA; pgRNA = pre-genomic RNA; HBsAg = hepatitis B surface antigen.)
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pgRNA during ongoing infection in addition 
to inhibition of rcDNA-cccDNA synthesis, 
presumably via inhibition of the capsid 
uncoating step. Second-generation RNA 
interference agents that primarily target 
HBsAg production are in development. In 
a HBV-infected chimeric mouse model an 
additive benefit of combination therapy 
of ARB-423 and ARB-1740, and further 
benefits with PEG-IFNα and entecavir 
have been demonstrated. Reduced cccDNA 
transcriptional activity was demonstrable.[83] 
The capsid assembly modulator JNJ-
56136379 prevents de novo infection 
of primary human hepatocytes (PHH) 
with hepatitis B virus. The compound 
induces the formation of empty HBV 
capsids with normal geometry and 
size. The compound is active across 
a broad panel of clinical isolates and is 
potentially additive to synergistic with 
nucleos(t)ide analogues. The compound 
may also block cccDNA formation in PHHs, 
resulting in the reduction of HBV RNA and 
antigens.[84,85] 
The combination of GLS4JHS and 
ritonavir was well tolerated and produced a 
rapid and substantial decrease in HBV-DNA 
levels in patients chronically infected with 
HBV.[86]
Regulation of immunity
Restoration of adaptive immunity remains 
a challenge. Chronic hepatitis B is 
associated with several identifiable levels of 
immune dysfunction, including functional 
exhaustion of HBV-specific CD8+ T 
cells, as a consequence of exposure to 
abundant quantities of HBsAg and HBeAg, 
expression of inhibitory molecules such as 
programmed cell death protein 1(PD-1), and 
consequently the loss of antigen-specific T 
cell effector function. Blocking expression of 
inhibitory regulatory receptors (checkpoint 
inhibition) could possibly restore functional 
T-cell activity to exhausted lymphoid 
cells. Blockade of the PD-1 pathway with 
woodchuck anti-programmed death 
ligand 1  (PD-L1 antibody), therapeutic DNA 
vaccination, and treatment with entecavir, 
as well as enhanced virus-specific T cell 
immunity, has led to resolution of chronic 
infection in woodchucks.[87] 
Experimental toll-like receptor (TLR) 
agonists suggest that HBV replication 
could be inhibited by the activation of 
innate immune responses in the liver. 
GS-9620, is an oral agonist of TLR-7. The 
immunological and pharmacodynamic 
effects are being studied in humans.[88] A 
dose-dependent induction of peripheral 
interferon-stimulated gene 15 (ISG15) gene 
expression has been observed, but without 
a clinically significant change in HBsAg 
concentrations.[89]
Recently Pallett et al.[90] demonstrated that 
myeloid-derived suppressor cells suppress T 
cell-mediated immunopathology in chronic 
hepatitis B: these cells expanded transiently 
in acute resolving hepatitis B infection but 
decrease in frequency prior to peak hepatic 
injury. During chronic infection, arginase-
expressing myeloid-derived suppressor 
cells and circulating arginase increased 
in phase with HBV replication without 
immunopathology, and thus L-arginine 
decreased. The myeloid-derived suppressor 
cells potently inhibited T cells in a partially 
arginase-dependent manner, demonstrating 
the possible potential of the arginase-
expressing suppressor cells to regulate liver 
immunopathology during hepatitis B.
Other novel molecular therapeutic 
strategies and immunological treatments 
include the possible application of 
therapeutic vaccines to boost HBV-specific 
T-cell responses or alter the dysfunctional 
immune response. Tarmogens, i.e. yeast-based 
immunotherapy platforms, have been used to 
make vaccine candidates expressing HBV X, S, 
and core antigens.[91] GS4774 is a genetically 
modified yeast organism engineered to 
express HBV antigens to activate T cells. 
Other possible therapeutic vaccines, 
including adenovirus fusion proteins, are 
currently being evaluated in clinical trials. 
SB 9200 is a unique oral prodrug of the 
dinucleotide SB9000, and acts as a retinoic 
acid-inducible gene 1 (RIG-I) activator.  The 
drug is thought to bind and activate RIG-I, 
thus increasing sensitivity to viral proteins, 
resulting in IFN-mediated antiviral immune 
responses in virus-infected cells, as well as 
to inhibit the packing reaction during HBV 
encapsidation (Fig. 8).
New markers of HBV 
infection
It is difficult to measure or monitor 
intrahepatic cccDNA levels or its 
transcriptional activity; testing requires the 
use of liver tissues, or surrogate markers 
in serum that accurately reflect infection 
through different phases of the disease. 
Various HBV particles released into 
peripheral blood are of increasing interest 
as surrogates to monitor cccDNA or 
transcriptional activity. 
HBV RNA 
It has become apparent that HBV may 
secrete, at low levels, RNA-containing 
particles. Numerous recent reports have 
demonstrated the detection of HBV RNA 
in serum samples of HBV-infected patients 
at 0.1 - 1% of HBV DNA levels, in the 
absence of antiviral treatment. The nature 
of the HBV RNA in the serum remains to 
be clarified. Some reports suggest that the 
RNA could be original pgRNA but it is not 
known whether these HBV RNA virions are 
infectious. There are technical challenges 
Fig. 8. HBV sensing could be amplified by RIG-I agonists resulting in IFN-mediated antiviral 
responses. (HBV = hepatitis B virus; TLRs = toll-like receptors; HBsAg = hepatitis B surface antigen; 
HBeAg = hepatitis B e-antigen; RIG-I = retinoic acid inducible gene 1 protein; IFNβ = interferon-beta; 
ISG = interferon-stimulated gene.)
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in discriminating HBV RNA with a large excess of rcDNA that is 
structurally related to CCC.[92] 
Since the DNA-containing virions are present at high 
concentrations, routine DNase digestion, to remove the viral DNA 
before RNA detection is required to completely remove all viral 
DNA. Serum HBV RNA is being assessed as a surrogate to monitor 
CCC DNA. When viral DNA synthesis is effectively suppressed 
with antiviral therapy, a rapid RNA decrease early during therapy 
with chain terminators may predict viral clearance or, equally, the 
persistence of serum HBV RNA might predict viral rebound after 
stopping treatment. 
Quantitative measurements of serum HBsAg may have 
prognostic significance. However, expression of HBsAg may be the 
predominant source of serum HBsAg, which may explain the loss 
of correlation between serum HBsAg levels and hepatic cccDNA, in 
later stages of HBV infection.
Hepatitis B core-related protein 
Hepatitis B core-related protein (HBcrAg) has been identified as an 
aberrantly processed pre-core protein comprising the entire pre-core 
region including the uncleaved signal peptide (a 29-residue N-terminal 
extension relative to HBc but similarly to HBeAg, devoid of the 
C-terminal arginine-rich domain which mediates HBV RNA and DNA 
binding by HBcAg (reviewed by Hu and Hu).[92] 
HBcrAg in serum samples has been tested in a number of clinical 
studies as a potential surrogate for monitoring cccDNA. Generally 
‘HBcrAg’ has been used to designate a combination of HBc and HBe 
and p22cr. HBcrAg concentrations correlate well with serum HBV 
DNA and HBsAg levels, and with HBcAg-positive hepatocytes.
Conclusion
Current therapies with nucleoside analogues achieve remission in 
most patients. Nucleoside analogues can be stopped in a proportion 
of patients. The majority of patients treated with nucleoside analogues 
require maintenance therapy and although these therapies have reduced 
morbidity and mortality from the disease, the majority are not cured. 
It is unclear whether all cccDNA chromatin would need to be 
eradicated for a cure of hepatitis B, or whether lowering levels to 
a lower threshold could reduce HBV replication and hence disease 
progression (as may be the case in inactive carriers). Unfortunately, 
there are no definitively proven serological surrogates for cccDNA for 
study in pilot phase experiments – these trials in patients may require 
liver biopsy to quantify tissue cccDNA. HBsAg quantitation may serve 
this purpose but phase 1 dose-finding studies may also require precise 
quantitation and characterisation of cccDNA in liver tissue.[93,94] 
Cures for hepatitis B will no doubt require multiple synergistic 
therapies to achieve either eradication from the host, or alternatively 
a functional cure. The complex dysfunctional immune response 
will require further understanding to remedy. Curative regimens 
will possibly demand a complex combination or sequence of agents, 
to result in viral suppression via nucleoside analogue treatment, 
selective cccDNA inhibitors or modifiers to deplete silence or 
degrade cccDNA, and restoration of the exhausted T-cell repertoire, 
as well as perhaps, agents to block the entry of HBV into the 
hepatocyte. Nonetheless a number of promising lines of treatment are 
being examined and regulatory pathways are being defined.[95] 
It is not yet clear at what stages of the disease and to what extent 
the dysfunctional adaptive immune response apparent in hepatitis B 
infection can be restored, and to what extent exhaustion of cytolytic 
T cells induced by high levels of exposure to hepatitis B antigens 
can be reduced by a combination of suppression of viral replication 
as well as blockade of inhibitory antibody. Neither are the risks of 
severe uncontrolled T-cell cytolytic responses fully ascertained. 
Painstaking empirical data are required. The correct sequencing and 
combinations of treatment with either host or viral targeting agents 
have yet to be established.
Many safety considerations exist. Nucleic acid-based gene 
knockdown and silencing molecules will need to achieve precise 
sequence specificity and be devoid of off-target biological interactions 
with proteins other than the targeted gene transcripts.
The management of chronic hepatitis B has advanced significantly, 
and treatments that effectively suppress the virus with no risk 
of resistance need to be widely applied. New agents to eliminate 
active replicative HBV infection or achieve a functional cure are 
being avidly sought. Their incorporation into strategies to optimise 
combination therapies will be tested over the next decade.
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